Roivant Sciences (ROIV) stock
Last close $38.66 on 2026-11-20 (-0.78%) · Sector: Healthcare
Roivant Sciences is a healthcare company that works to develop new medicines quickly, aiming to bring innovative treatments to patients. It makes money through its drug development work and any future medicines it brings to market, and it currently has very little revenue from sales.
The stock has returned 90.4% over the past year, well ahead of the S&P 500's 3.15%, and it trades 4.0% above its 50-day average and 18.1% above its 200-day average. Revenue is small but grew 100% in the latest period, and the company still reports losses on an operating basis. Insiders sold about $218.6 million of stock over the last 90 days and made no purchases, and the stock rose after 5 of its 5 recent earnings reports.
Key numbers
- Revenue (last 12 months): $0.04B
- Revenue growth: +100.0%
- Gross margin: 90.5%
- Operating margin: -1400.0%
- Debt to equity: 0.08
- Current ratio: 15.57
Quality score
Overall 63/100 · growth 100 · profitability 0 · financial health 89 · value None
Performance and risk
1-year return +90.4% vs S&P 500 +3.1% · volatility 48.2% (S&P 500 14.2%) · largest drop -20.2% · beta 1.10
Stock move the day after earnings
- 2026-02-06: +22.1%
- 2026-04-02: +1.8%
- 2026-05-20: +14.9%
- 2026-08-06: +1.5%
- 2026-11-09: +4.6%
Insider trades (12 months)
Bought $0.0M · sold $959.3M
ROIV stock research · ROIV options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.